Investor Presentaiton
ORION
Basis for the outlook - key contributors
40
40
Net sales EUR 1,340–1,410 million
↑ Innovative Medicines
NubeqaⓇ sales booked by Orion
✰ Assumed EUR 70 million NubeqaⓇ milestone
7 Branded Products
↑ Easyhaler Ⓡ product portfolio.
Entacapone products
✓ Generics and Consumer Health
Simdax® and dexmedetomidine products
Rest of the portfolio
Animal Health
Animal sedatives
Investor Presentation Orion Corporation
•
•
•
Operating profit in the range of EUR 270-310 million.
Expected growth driven by NubeqaⓇ royalties and
assumed EUR 70 million NubeqaⓇ milestone
•
Difficult to predict the exact level of royalties for a
strongly growing product
R&D expenses anticipated to increase clearly
In line with Orion's growth strategy
Sales and marketing expenses expected to increase
•
In line with Orion's growth strategyView entire presentation